Mitesh J Borad, MD

Zakharia, K., Miyabe, K., Wang, Y., Wu, D., Moser, C. D., Borad, M. J. & Roberts, L. R., Jan 1 2019, In : Translational Oncology. 12, 1, p. 143-153 11 p.

Research output: Contribution to journal › Article

Casein Kinase II

Cholangiocarcinoma

gemcitabine

Cisplatin

Heterografts

2 Citations

Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study)

Bergquist, J. R., Shah, H. N., Habermann, E. B., Hernandez, M. C., Ivanics, T., Kendrick, M. L., Smoot, R. L., Nagorney, D. M., Borad, M. J., Mc Williams, R. R. & Truty, M., Apr 1 2018, In : International Journal of Surgery. 52, p. 171-179 9 p.

Research output: Contribution to journal › Article

Gallbladder Neoplasms

Cohort Studies

Retrospective Studies

Adjuvant Chemotherapy

Gallbladder

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Mody, K., Mansfield, A., Vemireddy, L., Nygren, P., Gulbo, J. & Borad, M. J., Jan 1 2018, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journal › Article

Iron Chelating Agents

Chelating Agents

Iron

Clinical Trials

Safety

Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma

Kommalapati, A., Tella, S. H., Goyal, G., Borad, M. J., Alberts, S. R., Roberts, L. R., Hubbard, J. M., Durgin, L., Cleary, S. & Mahipal, A., Jan 1 2018, (Accepted/In press) In : HPB.

Research output: Contribution to journal › Article

Cholangiocarcinoma

Survival

Liver

Therapeutics

Insurance

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2⁺ breast cancer samples

Vasmatzis, G., Wang, X., Smadbeck, J. B., Murphy, S. J., Geiersbach, K. B., Johnson, S. H., Gaitatzes, A. G., Asmann, Y., Kosari, F., Borad, M. J., Serie, D. J., McLaughlin, S. A., Kachergus, J. M., Necela, B. M. & Thompson, E. A., Jul 13 2018, In : BMC Cancer. 18, 1, 738.

Research output: Contribution to journal › Article

Chromosomes, Human, Pair 8

Breast Neoplasms

Chromosomes, Human, Pair 17

Transcriptome

Genome

Mitesh J Borad, MD

Oncolytic Virotherapy in Hepatocellular Cancer

Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma

Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study)

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2⁺ breast cancer samples